What Коплавикс Treats: Main Uses and Benefits

The fixed combination of Acetylsalicylic Acid (ASA) and Clopidogrel is designed for secondary prevention—a relevant, long-term therapeutic strategy generally applied for managing the risk of recurrent vascular events in patients with established disease. A primary benefit is sustained anti-clotting support across major vascular domains. The medicine is associated with the secondary prevention of atherothrombotic events in adults, particularly when used as continuation therapy following acute coronary syndromes and post-interventional procedures like stenting.

This therapy is commonly used to help manage systemic vascular risk in conditions involving a history of Myocardial Infarction (heart attack), Ischemic Stroke or Transient Ischemic Attack (TIA), and after Coronary Stenting.

Reducing Risk After Acute Heart Events

This medicine is considered relevant for patients who have already experienced an event related to blocked coronary arteries. It is commonly used to help limit the formation of new, pathological blood clots, which may assist with reducing the risk of a recurring acute cardiac event. This process may assist with managing symptoms related to systemic imbalance.

Protection Following Stroke and TIA

The therapy is also considered relevant for managing systemic vascular risk following a clot-related Ischemic Stroke or a TIA. It is applied in addressing the risk of recurring neurological deficits and subsequent strokes, which assists with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Relief for Recurrent Vascular Risk

The medication is applied across conditions marked by heightened symptoms, helping patients cope more steadily with symptom fluctuations and supports the patient during difficult episodes by easing distress.

Eligibility Profile: Official Regulatory Information

Коплавикс (clopidogrel) is an antiplatelet agent with specific regulatory constraints on its use, based on patient condition and population group.

Classification	Population/Condition
Absolute Contraindication	Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
Absolute Contraindication	Known hypersensitivity to the active substance or components.
Absolute Contraindication	Severe hepatic impairment (severe liver disease).
Use Not Established	Pediatric population (children and adolescents).

Eligibility is typically established for adult patients receiving treatment for specified cardiovascular conditions. However, additional restrictions apply:

• Genetic Status: Patients identified as CYP2C19 poor metabolizers have a diminished antiplatelet response, which is a recognized limitation on the drug's effectiveness. Alternative treatments may be required in this population.
• Pregnancy/Lactation: Use during pregnancy is advised only if clearly needed due to limited human data. During breastfeeding, a decision must be made to either discontinue nursing or discontinue the medication.
• Organ Impairment: Therapeutic experience is limited in patients with renal impairment and moderate hepatic disease; caution is required in these groups.

Interactions with other medicines and products

Official regulatory documents classify interactions with Коплавикс (Clopidogrel and Acetylsalicylic Acid) into two primary domains: Pharmacodynamic and Pharmacokinetic.

Pharmacodynamic Interaction Restrictions

Co-administration with other medicines that affect blood clotting, such as Oral Anticoagulants, Heparin, Thrombolytics, and Glycoprotein IIb/IIIa Inhibitors, is generally not recommended or requires caution due to a documented additive effect that increases the risk of bleeding. Similarly, combining the medication with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or Selective Serotonin Reuptake Inhibitors (SSRIs) increases the risk of gastrointestinal and other bleeding, respectively.

Pharmacokinetic and Exposure Alterations

Metabolic inhibition poses a significant interaction concern. Strong inhibitors of the enzyme CYP2C19, including Omeprazole and Esomeprazole, are documented to reduce the exposure of Clopidogrel's active metabolite, which diminishes its antiplatelet activity. Conversely, strong inducers like Rifampicin can increase exposure and potentiate bleeding risk. Additionally, caution is advised with CYP2C8 substrates (e.g., Repaglinide) and CYP2C9 substrates (e.g., Phenytoin) due to potential inhibition by Clopidogrel.

Administration Requirements

Regulatory information states that the medication must be discontinued 7 days prior to elective surgery that carries a major risk of bleeding. The combination is also formally contraindicated for patients with severe hepatic or severe renal impairment.

Irreversible Blockade of Key Platelet Signal Amplifiers

Коплавикс is a fixed-dose combination that provides Dual Antiplatelet Therapy (DAPT) by simultaneously disrupting two distinct, critical molecular pathways necessary for the activation and clumping of platelets. This mechanism focuses on the permanent deactivation of two molecular targets: the platelet enzyme Cyclooxygenase-1 ( COX-1) by Acetylsalicylic Acid (ASA), and the ADP receptor P2Y12 by the Clopidogrel active metabolite. ASA stops the synthesis of the aggregating signal Thromboxane A2 ( TxA2), while Clopidogrel blocks the P2Y12 receptor. By irreversibly modifying these molecular targets, the drug ensures that platelets cannot respond effectively to pro-clotting stimuli, leading to a sustained functional impairment of aggregation.

Synergy and the Functional Life of the Platelet

The synergistic action arises because the two components suppress non-redundant amplification cascades in the platelet, resulting in a more pronounced suppression of aggregation than targeting a single pathway. Because both ASA and the active Clopidogrel metabolite bind covalently (irreversibly), the effect is persistent, lasting for the entire 7–10 day lifespan of the affected platelet regardless of plasma drug concentration. This provides a constant reduction in overall platelet reactivity.

How to Use Коплавикс

Коплавикс is a fixed-dose combination of Clopidogrel and Acetylsalicylic Acid (ASA) indicated for antiplatelet therapy. The medicine is designed to be used as continuation therapy, meaning its administration follows an initial treatment phase where the components were taken as separate tablets.

---

Official Administration Guidelines

The established usage protocol defines the methods for taking the medicine, ensuring consistent antiplatelet support.

Category	Official Instruction
Route of Administration	Oral use only, as a film-coated tablet.
Dosing Schedule	One fixed-dose tablet (75 mg Clopidogrel / 75 mg ASA or 75 mg Clopidogrel / 100 mg ASA) taken once daily.
Timing	The tablet may be taken with or without food.
Duration	Used for long-term support; for some conditions, clinical data supports use up to 12 months.

---

Procedural and Population Rules

Adherence to the schedule requires following specific instructions for common usage scenarios:

• Missed Dose: If less than 12 hours have passed since the scheduled time, the dose should be taken immediately. If more than 12 hours have passed, the missed dose must be skipped, and the regular schedule resumed.
• Pediatric Use: The medicine is not recommended for use in individuals under 18 years of age, as safety and efficacy are not established in this population.
• Older Adults: For specific acute cardiac scenarios, initiation of the Clopidogrel component (before switching to the FDC) is done without a loading dose in patients over 75 years of age.

Коплавикс: Recent Clinical Evidence

The research base for Коплавикс, a fixed-dose combination of clopidogrel and acetylsalicylic acid (ASA), includes large clinical trials exploring the outcomes of the two medicines taken together, and regulatory studies confirming that the single combination pill is absorbed by the body similarly to the separate tablets.

---

Evidence Base for Secondary Prevention Following Acute Coronary Events

The primary research examining this dual therapy was conducted in large-scale Randomized Controlled Trials (RCTs) involving adult patients following an Acute Coronary Syndrome (such as myocardial infarction) or coronary stenting. The studies examined a composite endpoint combining Cardiovascular Death, non-fatal Myocardial Infarction, or non-fatal Stroke over intermediate and long-term periods. Findings describe patterns observed in the studies related to the frequency of these major events. The study designs also included assessing whether major bleeding was associated with the dual therapy compared to monotherapy.

---

Research Supporting Use After Acute Stroke or TIA

Research examining the dual therapy for stroke recurrence was evaluated in short-term RCTs that studied adult patients enrolled in the acute phase immediately after a minor Ischemic Stroke or Transient Ischemic Attack (TIA). Researchers focused on outcomes describing episodic or acute changes over very brief observation windows (e.g., 30 or 90 days). Research highlights changes measured during the study period related to the rate of recurrent stroke. Beyond this acute phase, trials did not consistently report a sustained difference, and long-term effects are not fully established for continuous use in this population.

---

The Regulatory Foundation of the Fixed-Dose Combination

The approval of the single combination tablet is not based on new clinical outcome trials. Instead, the product relies on Bioequivalence (BE) Studies conducted in healthy adult volunteers. These studies monitored pharmacokinetic (PK) measurements to explore whether the single pill was absorbed by the body at a comparable rate and extent to the separate medicines. The regulatory basis allows the fixed-dose product to be utilized based on the known outcomes of the separately administered components.

---

Evidence Gaps and Uncertainty

Evidence concerning the full implications of the duration of dual therapy is still emerging, particularly for use extending beyond one year after certain acute events. Data for certain groups, such as children or pregnant individuals, remains insufficient, as major trials primarily enrolled adults. Ultimately, research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Common questions about Коплавикс (FAQ)

Q: What is Коплавикс?

A: Коплавикс is a combination medication containing clopidogrel and acetylsalicylic acid (aspirin). It is primarily used to prevent serious cardiovascular events like heart attack and stroke in people who have already had a heart attack or stroke, or who have been diagnosed with certain circulation problems.

Q: How does Коплавикс work?

A: Коплавикс works by combining the effects of its two active ingredients:

• Clopidogrel is an antiplatelet agent that helps prevent platelets in the blood from sticking together and forming harmful clots.
• Acetylsalicylic acid (aspirin) is also an antiplatelet agent, and at the low dose in this medication, it also works to reduce blood clot formation.

This combination offers a dual approach to blood clot prevention.

Q: What are the side effects of Коплавикс?

A: The most common and serious side effect is an increased risk of bleeding because the medication prevents blood from clotting easily. This can manifest as easy bruising, nosebleeds, or internal bleeding, particularly in the stomach or intestines. Less common side effects may include stomach discomfort, indigestion, or diarrhea.

Q: Who should not take Коплавикс?

A: You should not take Коплавикс if you have:

• An active pathological bleeding (such as a stomach ulcer or bleeding in the brain).
• A severe liver impairment.
• An allergy to clopidogrel, aspirin, or any of the other ingredients.

It is also generally not recommended for women in the third trimester of pregnancy.

Q: Can I take other medications with Коплавикс?

A: Коплавикс can interact with several other medications, which can increase the risk of bleeding or reduce its effectiveness. It is very important to inform your healthcare provider about all medications, supplements, and herbal products you are taking, especially other anticoagulants (blood thinners), NSAIDs (non-steroidal anti-inflammatory drugs) like ibuprofen, or certain proton pump inhibitors (PPIs).

Storage and Disposal of KOPLAVIX

KOPLAVIX (clopidogrel and acetylsalicylic acid) must be stored under specific conditions to maintain its effectiveness. Regulatory information states that the medicine must be stored below 25 C to 30 C and should be protected from light and moisture. To achieve this, it must remain in its original container or blister pack until administration. The medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Requirements

Do not dispose of KOPLAVIX by flushing it down the toilet or throwing it into household waste. Unused or expired tablets must be disposed of through a dedicated drug take-back program or as advised by a pharmacist, following local regulatory requirements for pharmaceutical waste.